Dengue fever vaccines have undergone significant development, with notable advancements in research and clinical trials. Dengue, caused by the Dengue virus transmitted through Aedes mosquitoes, poses a substantial global health threat, and the pursuit of an effective vaccine has been a priority. Among the prominent candidates is Dengvaxia (CYD-TDV) by Sanofi Pasteur, the first Dengue vaccine licensed in several countries. However, its usage is restricted to individuals with prior Dengue exposure due to concerns about potential increased severity in Dengue-naive individuals. Ongoing research focuses on developing vaccines that provide broad protection across multiple Dengue virus serotypes, addressing the challenges of incomplete immunity and the risk of severe Dengue in certain populations. Several promising candidates are in various stages of clinical evaluation, offering hope for a more widely applicable and efficacious Dengue vaccine in the future. As the field of Dengue vaccine development is dynamic, it is essential to stay informed about the latest advancements and regulatory approvals beyond my last update in January 2022.
Submit your abstract Today
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : Prophylactic and Molecular Approaches for Mitigating Human Influenza A Viruses: i. Evaluating influenza Vaccine Effectiveness in the Older population ii. Down-regulation of influenza virus genes with novel siRNA-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Development of a Novel Multi-component Vaccine to Address the Burden of Otitis Media in High-Risk Populations
Ayesha Zahid, Griffith University, Australia
Title : Targeting resistance: New 4-substituted pyrazolidine and isoxazolidine as antibiotics with interesting antimicrobial activities
Yousfi Tarek, Nationale Research for Biotechnology Research Center, Algeria
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Immunosuppression in COVID-19 Patients and Emerging Fungal Infections: Vaccines, Diagnosis and Strategies to Treat Comorbidities
K R Aneja, Kurukshetra University, India
Title : Immunogenicity and Cryo-EM structure of native-like HIV-1 Clade-C envelope trimers derived from a pediatric elite-neutralizer
Swarandeep Singh, All India Institute of Medical Sciences, India
Title : Why is the vaccine life-threatening if people get a fever after a COVID-19 vaccination
Yacob Mathai, Marma Health Centre, India
Title : Barriers to polio eradication in South Asia: A systematic review
Awranoos Ahadi, Bolan Medical College, Pakistan